Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 120, Issue 5, Pages 512-521
Publisher
Springer Nature
Online
2019-02-15
DOI
10.1038/s41416-018-0373-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Breaking Kuhn's paradigm in advanced hepatocellular carcinoma
- (2018) David J. Pinato HEPATOLOGY
- Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells
- (2018) Federica Fratangelo et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
- (2018) Lorenza Rimassa et al. LANCET ONCOLOGY
- Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells
- (2018) Luca Mologni et al. NEOPLASIA
- Emerging tyrosine kinase inhibitors for the treatment of hepatocellular carcinoma
- (2017) Laure de Rosamel et al. EXPERT OPINION ON EMERGING DRUGS
- Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents
- (2017) Qiang Gao et al. GASTROENTEROLOGY
- Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials
- (2017) Richard Jackson et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior
- (2017) David J. Pinato et al. OncoImmunology
- Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma
- (2016) Jordi Bruix et al. GASTROENTEROLOGY
- Gene of the month:Axl
- (2016) Matthew Brown et al. JOURNAL OF CLINICAL PATHOLOGY
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
- (2016) M. A. Miller et al. Cancer Discovery
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma
- (2015) Naoshi Nishida et al. DIGESTIVE DISEASES
- Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
- (2015) Victoria Tovar et al. GUT
- Axl activates autocrine transforming growth factor-β signaling in hepatocellular carcinoma
- (2015) Patrick Reichl et al. HEPATOLOGY
- New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
- (2015) Makoto Chuma et al. HEPATOLOGY RESEARCH
- TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition
- (2015) D J Pinato et al. ONCOGENE
- Growth-Factor-Driven Rescue to Receptor Tyrosine Kinase (RTK) Inhibitors through Akt and Erk Phosphorylation in Pediatric Low Grade Astrocytoma and Ependymoma
- (2015) Mariska Sie et al. PLoS One
- Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma
- (2014) David J. Pinato et al. ADVANCES IN ANATOMIC PATHOLOGY
- Positron Emission Tomography Imaging with 18F-Labeled ZHER2:2891 Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies
- (2014) S. Trousil et al. CLINICAL CANCER RESEARCH
- Intratumor Heterogeneity in Hepatocellular Carcinoma
- (2014) J. Friemel et al. CLINICAL CANCER RESEARCH
- Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
- (2014) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors
- (2014) C. Feneyrolles et al. MOLECULAR CANCER THERAPEUTICS
- Treatment of intermediate-stage hepatocellular carcinoma
- (2014) Alejandro Forner et al. Nature Reviews Clinical Oncology
- Hepatoma SK Hep-1 Cells Exhibit Characteristics of Oncogenic Mesenchymal Stem Cells with Highly Metastatic Capacity
- (2014) Jong Ryeol Eun et al. PLoS One
- Current management of hepatocellular carcinoma
- (2014) Parissa Tabrizian WORLD JOURNAL OF GASTROENTEROLOGY
- Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
- (2013) M Kaliszczak et al. BRITISH JOURNAL OF CANCER
- A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
- (2013) M Kaliszczak et al. BRITISH JOURNAL OF CANCER
- An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: correlation with tumour phenotype and survival outcomes
- (2013) D J Pinato et al. BRITISH JOURNAL OF CANCER
- Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma
- (2013) Hsin-Jung Lee et al. CARCINOGENESIS
- Postprogression survival of patients with advanced hepatocellular carcinoma: Rationale for second-line trial design
- (2013) Maria Reig et al. HEPATOLOGY
- The receptor tyrosine kinase Axl in cancer: Biological functions and therapeutic implications
- (2013) Juliano D. Paccez et al. INTERNATIONAL JOURNAL OF CANCER
- The receptor tyrosine kinase Axl regulates cell–cell adhesion and stemness in cutaneous squamous cell carcinoma
- (2013) M A Cichoń et al. ONCOGENE
- FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma
- (2012) Tokuzo Arao et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial
- (2012) Jordi Bruix et al. JOURNAL OF HEPATOLOGY
- Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
- (2012) Marie-José Blivet-Van Eggelpoël et al. JOURNAL OF HEPATOLOGY
- Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
- (2012) David James Pinato et al. Journal of Thoracic Oncology
- Medical therapies for hepatocellular carcinoma: a critical view of the evidence
- (2012) Augusto Villanueva et al. Nature Reviews Gastroenterology & Hepatology
- The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma
- (2011) Alvarez Hector et al. CANCER BIOLOGY & THERAPY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
- (2010) S. J. Holland et al. CANCER RESEARCH
- AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma
- (2010) M Z Xu et al. ONCOGENE
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started